Basal cell carcinoma is the most common malignancy in humans, and it is also the mostfrequent periocular malignancy. Although a slow-growing tumor, it can lead to significant morbidityin the ...

Trudy Oliver, professor of pharmacology and cancer biology, is part of a team of scientists that recently published a study uncovering a major shift in how scientists understand small-cell lung cancer ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...

Add Yahoo as a preferred source to see more of our stories on Google. Andy Ryan is pushing through the stigma of talking about prostate cancer after losing his uncle and grandfather to the disease - ...

Michael Clarke: Former Australian cricketer Michael Clarke has opened up about his ongoing fight with skin cancer, revealing he has had several melanomas and other cancers removed from his face and ...

Basal cell carcinoma is the most common skin cancer, often caused by UV exposure, and originates in the epidermis's basal cells. Diagnosis involves clinical examination and biopsy to confirm BCC and ...

Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers. Promising initial testing results, ...

Libtayo is also now reimbursed in Alberta for the NSCLC combination therapy indication and locally advanced BCC indication as described above. Libtayo is also reimbursed in Québec by Régie de ...

WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical ...